![]() The LAR subtype has the lowest pCR rate (21.4%).Īlthough breast cancer has traditionally been considered a non-immunogenic tumor, multiple studies have shown that TNBC can stimulate the immune system. They are also the subtype with the highest pathological complete response (pCR) rate (65.6%) followed by BL2 (36.4%) in a cohort of patients treated with platinum-based neoadjuvant therapy ( n = 97). BL1 and IM tumors have a higher sensitivity to DNA-damaging agents such as platinum and are associated with a young age at diagnosis. Lehmann et al identified 6 different subtypes using DNA and RNA profiles in TNBC each with particular characteristics. Most basal-like tumors are included in TNBCs (they represent 70%-80% of the TNBCs). Perou et al proposed a classification based on expression patterns, subdivided into 4 clinical molecular subtypes (luminal A, luminal B, HER2 enriched and basal-like). In the neoadjuvant setting, the use of immunotherapy has recently been approved.īased on efforts in genetic studies, breast cancer was divided into molecular subtypes. However, this has recently changed with the introduction of immunotherapy in patients with programmed death ligand 1 (PD-L1) expressing tumors, both in unresectable locally advanced/metastatic disease. Unlike other subtypes, historically, TNBC has had no other systemic treatment options other than chemotherapy which has been the cornerstone of treatment for many years. It is associated with a high incidence of visceral metastasis (predominance of hepatic, pulmonary and central nervous system metastasis), a high risk of early recurrence and a worse prognosis. Triple-negative breast cancer (TNBC) which effects approximately 15 - 20% of all patients, is a heterogeneous, complex disease with a more aggressive behavior than other subtypes of breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |